Replies to post #150615 on Biotech Values

[iwfal]

The late relapses you’re referring to occurred in the PILOT study, which tested ABT-450/r + ABT-072 (a non-nuke) + ribavirin; i.e. it had no NS5A inhibitor. The study we’re discussing today, called AVIATOR, tested ABT-450/r + ABT-267 (a newer non-nuke than ABT-072) + ABT-333 (NS5A) + ribavirin.

Thanks for the clarification. Obviously that should result in lesser late relapse - but the interesting question is how much less even the lesser regimen got >90% EOT response (if I remember correctly) and yet had meaningful late relapse.